公司資料
Halozyme Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- HALO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
103.00 USD (+4.40%)
收盤價
最後更新: 2026年8月17日
7.86B USD
市值
股價為何變動
As of Aug 17, 2026, HALO closed up 4.40% at $103.00. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Halozyme is a U.S.-based specialty biotech company. It sits in platform-enabled drug delivery and oncology-adjacent therapeutics.
商業模式特徵
The company generates value through royalty income, partner relationships, and technology licensing tied to subcutaneous formulation. Investors follow licensing growth, partner adoption, and whether the technology platform continues to expand across the industry.
生技產業定位
Halozyme occupies a unique position in biotech because it monetizes platform technology rather than relying only on its own clinical pipeline. That makes it less binary than many development-stage peers, but still catalyst-sensitive around deal flow and partner uptake.
未來催化劑
- Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal. The stock moves when royalty durability and partner breadth both keep expanding.
近期新聞
- 01
- 02
- 03
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。